Retatrutide vs Ozempic: Phase 3 TRIUMPH-1 Data Compared
Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors. Ozempic (semaglutide) is a single agonist hitting only GLP-1. As of August 2026, retatrutide has Phase 3 topline results and semaglutide has an FDA approval with years of post-market data, which is the difference that actually matters for anyone deciding on treatment this year.
Status as of August 2026: Retatrutide is investigational. Topline Phase 3 TRIUMPH-1 results were announced May 21, 2026; TRIUMPH-2 and TRIUMPH-3 have not read out and no FDA submission has been announced. Ozempic is approved and marketed for type 2 diabetes; Wegovy, the same molecule at a higher dose, is approved for chronic weight management.
Head-to-Head Summary
Every efficacy figure below is a cross-trial comparison. Retatrutide and semaglutide have never been tested against each other in a randomized trial, so treat the gap as an estimate rather than a measured difference.
| Factor | Retatrutide | Ozempic (Semaglutide) |
|---|---|---|
| Receptor targets | GLP-1, GIP, glucagon (triple) | GLP-1 only (single) |
| Regulatory status | Investigational, not approved | FDA approved (diabetes 2017; Wegovy for weight loss 2021) |
| Best Phase 3 weight loss | 28.3% at 80 weeks (12 mg, TRIUMPH-1) | Roughly 15% at comparable maintenance timepoints |
| Extended-duration data | 30.3% at 104 weeks (BMI 35+ subgroup, n=532) | Multi-year post-market safety and efficacy data |
| Pivotal trial size | 2,339 (TRIUMPH-1) | Varies by trial; STEP program totals in the thousands |
| Nausea, top dose | 42.4% (12 mg) vs 14.8% placebo | Roughly 40-50% during escalation |
| Discontinuation for AEs, top dose | 11.3% (12 mg) vs 4.9% placebo | Typically single digits |
| Dosing | Once weekly subcutaneous, 2 mg start | Once weekly subcutaneous, 0.25 mg start |
| Can you get it today | No | Yes, with a prescription |
| Manufacturer | Eli Lilly | Novo Nordisk |
For the single-agonist side of this comparison in more depth, see Ozempic vs Wegovy and which GLP-1 is best for weight loss.
What TRIUMPH-1 Actually Showed
TRIUMPH-1 (NCT05929066) was a randomized, double-blind, placebo-controlled Phase 3 trial in 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, excluding people with diabetes. Topline results were announced May 21, 2026.
- 4 mg: 19.0% mean weight loss at 80 weeks
- 9 mg: 25.9% at 80 weeks
- 12 mg: 28.3% at 80 weeks
- Responder rate: 45.3% of the 12 mg group lost 30% or more of body weight
A prespecified blinded extension continued 532 participants with baseline BMI of 35 or higher out to 104 weeks at their maximum tolerated dose. Participants originally randomized to 12 mg reached 30.3% mean loss, the figure most often quoted in headlines. That number comes from a selected subgroup that tolerated two years of treatment, not the full trial population.
Full detail on the trial: retatrutide TRIUMPH-1 results. Note that the earlier retatrutide figure that circulated for years, 24.2% at 48 weeks, came from the smaller Phase 2 trial (n=338, placebo-controlled, published in the New England Journal of Medicine in 2023). That figure is now superseded by TRIUMPH-1 and should not be cited as current.
Triple vs Single Agonism: The Mechanistic Argument
Ozempic activates one receptor. Retatrutide activates three.
- GLP-1 receptor (shared by both drugs): suppresses appetite, slows gastric emptying, improves glucose-dependent insulin release
- GIP receptor (retatrutide only): improves insulin sensitivity and appears to blunt some of the nausea burden of GLP-1 agonism at matched efficacy
- Glucagon receptor (retatrutide only): raises resting energy expenditure and hepatic fat oxidation
The GLP-1 arm reduces how much you eat. The glucagon arm increases how much you burn. That combination is the mechanistic thesis behind retatrutide, and TRIUMPH-1 is the first large trial to test it at Phase 3 scale. The glucagon arm is also why cardiovascular monitoring gets more attention with retatrutide than with a pure GLP-1 drug like Ozempic, since glucagon agonism can raise heart rate.
Side Effects and Tolerability
TRIUMPH-1 adverse event rates by dose (4 mg, 9 mg, 12 mg) against placebo:
| Adverse event | 4 / 9 / 12 mg | Placebo |
|---|---|---|
| Nausea | 28.6% / 38.4% / 42.4% | 14.8% |
| Diarrhea | 25.2% / 34.1% / 32.0% | 13.5% |
| Constipation | 23.8% / 25.9% / 26.1% | 10.9% |
| Vomiting | 10.6% / 22.8% / 25.3% | 4.8% |
| Discontinued for AEs | 4.1% / 6.9% / 11.3% | 4.9% |
Ozempic's dose-escalation side effects are the same general class, GI upset that concentrates in the first weeks after each dose increase, backed by years of post-market reporting. Both drugs carry FDA warning language for pancreatitis risk and, from animal studies, thyroid C-cell tumor risk; neither should be used by anyone with a personal or family history of medullary thyroid cancer or MEN2.
See also retatrutide side effects and Wegovy side effects.
Approval Status and Access
Ozempic is FDA-approved for type 2 diabetes and widely available from pharmacies nationwide with a prescription; Wegovy, the same molecule at a higher dose, is FDA-approved specifically for chronic weight management. Both have multiple years of post-approval monitoring.
Retatrutide cannot be prescribed or dispensed as an approved medication anywhere. Lilly has said additional Phase 3 readouts are expected during 2026, including TRIUMPH-2 in adults with obesity and type 2 diabetes and TRIUMPH-3 in adults with established cardiovascular disease. A new drug application would follow those readouts, and FDA review typically takes another 10 to 12 months after submission. There is no announced submission date, so any specific approval month circulating online is speculation.
On the gray market: vials sold online as research-use-only retatrutide sit outside the regulated supply chain with no verified identity, purity, sterility, or dose accuracy. Read retatrutide availability and research peptides before assuming what arrives in the mail matches the label. Track approval status at retatrutide FDA approval.
Cost
Ozempic list price runs roughly $900-$1,300 per month uninsured, though many insurance plans cover it for diabetes and copay programs can bring that down substantially. Wegovy pricing is similar before insurance. Retatrutide has no launch price because it is not approved; compounded research-use vials are sold outside the regulated market at prices that carry no guarantee of accuracy since the product itself is unverified. See Ozempic cost and Wegovy cost for current, date-stamped figures, and retatrutide cost for what is knowable about the gray market today.
Who Should Choose What
Ozempic or Wegovy is the practical choice for anyone who needs treatment now: FDA approval, broad pharmacy access, insurance coverage in many plans, and years of established safety data. Retatrutide is not a choice available to anyone today. If you've plateaued on semaglutide, the near-term alternative a provider can actually prescribe is tirzepatide (Mounjaro or Zepbound), not retatrutide. See semaglutide vs tirzepatide.
Switching between GLP-1 class drugs should only be done under provider guidance, since the medications differ in potency and titration schedule and switching abruptly can cause appetite rebound or unexpected side effects.
Frequently Asked Questions
On weight loss, the Phase 3 numbers favor retatrutide. Retatrutide 12 mg produced 28.3% mean weight loss at 80 weeks in TRIUMPH-1. Semaglutide (Ozempic/Wegovy) produces roughly 15% at comparable maintenance timepoints in its own trials. The two have never been tested against each other in a randomized trial, so this is a cross-trial comparison, not a head-to-head result. Ozempic is also FDA-approved and available today; retatrutide is investigational and cannot be legally prescribed or dispensed as of August 2026.
No. There is no completed randomized trial that assigned patients to retatrutide or semaglutide and measured both directly. TRIUMPH-1, the Phase 3 retatrutide trial, was placebo-controlled. Every number on this page comparing the two drugs is a cross-trial estimate, which overstates precision when baseline weight, trial length, and titration schedules differ between studies.
Eli Lilly announced topline TRIUMPH-1 results on May 21, 2026. In 2,339 adults with obesity or overweight plus at least one weight-related comorbidity and no diabetes (NCT05929066), mean weight loss at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg. A prespecified 104-week extension in 532 participants with baseline BMI of 35 or higher reached 30.3% mean loss in the 12 mg arm. Full peer-reviewed publication had not appeared as of this writing.
Ozempic (semaglutide) is FDA-approved for type 2 diabetes; Wegovy, the same molecule at a higher dose, is FDA-approved for chronic weight management. Retatrutide is investigational. No FDA submission date has been announced as of August 2026, and Lilly has said additional Phase 3 readouts, including TRIUMPH-2 and TRIUMPH-3, are expected during 2026 before any filing would follow.
Not legally as a medication. Retatrutide is investigational, so no pharmacy can dispense it and no licensed provider can prescribe it as an approved drug. Vials sold online as research chemicals sit outside the regulated supply chain, are not made under pharmaceutical manufacturing standards, and carry no verified identity, purity, sterility, or dose accuracy.
The gastrointestinal side effect class is the same, but retatrutide’s rates climb with dose in TRIUMPH-1: nausea was 28.6%, 38.4%, and 42.4% at 4/9/12 mg versus 14.8% on placebo, and discontinuation for adverse events was 4.1%, 6.9%, and 11.3% versus 4.9% on placebo. Ozempic’s dose-escalation side effects are well documented after years of post-market use; see our dedicated breakdown for specifics.
GLP-1 agonism, which is all Ozempic does, mainly reduces energy intake through appetite suppression and slowed gastric emptying. Retatrutide adds GIP agonism, which improves insulin sensitivity and appears to blunt some of the nausea burden of GLP-1 agonism at matched efficacy, and glucagon receptor agonism, which raises resting energy expenditure and hepatic fat oxidation. Combining reduced intake with increased expenditure is the mechanistic argument for a triple agonist outperforming a single agonist, and TRIUMPH-1 is the first large trial to test that combination at Phase 3 scale.
Waiting has a real cost. Retatrutide has no approval date, two more Phase 3 readouts pending, and no announced launch price. Ozempic and Wegovy are approved, available, and backed by years of post-market safety data. If a provider considers you a candidate for treatment now, the usual clinical reasoning is to treat now and reassess when new options actually reach the market. This is a decision for you and a licensed clinician, not a comparison table.
Informational only, not medical advice. Retatrutide is an investigational drug not approved by the FDA or any other regulator as of August 2026 and cannot be legally prescribed or dispensed. TRIUMPH-1 figures are from Eli Lilly's topline announcement of May 21, 2026; full peer-reviewed results had not published as of this writing and numbers may be revised. Ozempic comparisons are cross-trial, not head-to-head. Talk to a licensed clinician about treatment decisions.